Dermatomyositis in Association With SARS‐CoV‐2 Infection or COVID‐19 Vaccine
Authors' conclusion
This retrospective review revealed a strong temporal relationship between DM symptoms and COVID-19 infection or vaccination in 12.2% of all patients with DM evaluated in our clinic during the pandemic.
Study context
- Population
- Patients treated for Dermatomyositis (DM) in the Division of Rheumatology, March 1, 2020 to October 31, 2022
- Participants
- 98 patients
- Outcome
- New-onset DM or relapse of preexisting DM following SARS-CoV-2 infection or COVID-19 vaccination
Methodological detailsretrospective chart review, single-institution
- Retrospective chart review
- Single-institution
Main finding
As reported in the abstract
DM symptoms (incident or relapse) following infection or vaccination
Patients with DM symptoms after infection or vaccination
12 of 98
12.2%
Observational data: associations, not effects.
Further findings
Trigger among the 12 patients with incident disease or relapse
- Postinfection symptoms
- 7 (58.3%)
- Postvaccination symptoms
- 8 (66.7%)
- Symptoms after both infection and vaccination
- 3
Time to symptom onset
Days
- After COVID-19 infection, mean
- 3.2
- After COVID-19 infection, median
- 0.5
- After COVID-19 vaccination, mean
- 5.75
- After COVID-19 vaccination, median
- 3.5
Antibody profile among the 12 patients
- Positive myositis-specific antibody
- 9 of 12 (75%)
- Myositis-associated antibodies
- 3 (25%)
Vaccine type
- No predominant vaccine associated with postvaccination DM symptoms
Original publication
Dermatomyositis in Association With SARS‐CoV‐2 Infection or COVID‐19 Vaccine. Arthritis Care Res (Hoboken). Published 3 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →